Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2312-2319.e1

  Acosta, Andres ^a   Camilleri, Michael ^a   Kolar, Gururaj ^a   Iturrino, Johanna ^a   Szarka, Lawrence A ^a   Boldingh, Amy ^a   Burton, Duane ^a   Ryks, Michael ^a   Rhoten, Deborah ^a   Zinsmeister, Alan R ^b   Spence, Sharon C ^c   Gottesdiener, Keith ^c   Bouras, Ernest P ^d   Vazquez Roque, Maria I ^d  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c Rhythm Pharmaceuticals   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Bowel Function; Gastric Emptying; Ghrelin Receptor; SBTT

Indexed keywords

PLACEBO; RELAMORELIN; GASTROINTESTINAL AGENT; OLIGOPEPTIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BLOATING; BODY MASS; CHRONIC CONSTIPATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FECES ANALYSIS; FEMALE; GASTROINTESTINAL TRANSIT; HEADACHE; HEARTBURN; HUMAN; INCREASED APPETITE; INJECTION SITE REACTION; INTESTINE FUNCTION; NAUSEA; NOSE OBSTRUCTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUS CONGESTION; STOMACH EMPTYING; TREATMENT DURATION; TREATMENT WITHDRAWAL; COLON; CONSTIPATION; DRUG EFFECTS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; COLON; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HUMANS; INJECTIONS, SUBCUTANEOUS; OLIGOPEPTIDES; PLACEBOS; TREATMENT OUTCOME;

EID: 84947489232     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.04.184     Document Type: Article

References (29)

1. Talley N.J., Weaver A.L., Zinsmeister A.R., et al. Functional constipation and outlet delay: a population-based study. Gastroenterology 1993, 105:781-790.
2. Camilleri M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin Pharmacol Ther 2011, 91:44-59.
3. Camilleri M., Papathanasopoulos A., Odunsi S. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009, 6:343-352.
4. van der Lely A.J., Tschop M., Heiman M.L., et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004, 25:426-457.
5. Trudel L., Tomasetto C., Rio M.C., et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002, 282:G948-G952.
6. Dass N.B., Munonyara M., Bassil A.K., et al. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience 2003, 120:443-453.
7. Peeters T.L. Central and peripheral mechanisms by which ghrelin regulates gut motility. J Physiol Pharmacol 2003, 54(Suppl 4):95-103.
8. Kitazawa T., Nakamura T., Saeki A., et al. Molecular identification of ghrelin receptor (GHS-R1a) and its functional role in the gastrointestinal tract of the guinea-pig. Peptides 2011, 32:1876-1886.
9. Avau B., Carbone F., Tack J., et al. Ghrelin signaling in the gut, its physiological properties, and therapeutic potential. Neurogastroenterol Motil 2013, 25:720-732.
10. Avau B., Carbone F., Tack J., et al. Ghrelin signaling in the gut, its physiological properties, and therapeutic potential. Neurogastroenterol Motil 2013, 25:720-732.
11. Camilleri M., Acosta A. Relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil 2015, 27:324-332.
12. Shin A., Camilleri M., Busciglio I., et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013, 11:1453-1459.
13. Shin A., Camilleri M., Busciglio I., et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013, 36:41-48.
14. Lembo A., Camilleri M., McCallum R., et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014, 146(Suppl 1):S158-S159.
15. Van der Ploeg L., Laken H., Sharma S., et al. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci 2014, 109:20-29.
16. Manabe N., Wong B., Camilleri M., et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010, 22:293.
17. Kolar G.J., Camilleri M., Burton D., et al. Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice. Neurogastroenterol Motil 2014, 26:131-138.
18. Talley N.J., Phillips S.F., Melton J., et al. A patient questionnaire to identify bowel disease. Ann Intern Med 1989, 111:671-674.
19. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
20. Lembo A., Camilleri M. Chronic constipation. N Engl J Med 2003, 349:1360-1368.
21. Kaplan L., White J., Spence S., et al. RM-131, a novel ghrelin analog, demonstrates potent prokinetic activity in phase 1 single- and multiple-dose studies in healthy volunteers. Am J Gastroenterol 2012, 107:S706-S707.
22. Deiteren A., Camilleri M., Bharucha A.E., et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010, 22:415-423. e95.
23. Zinsmeister A.R., Burton D., Camilleri M. Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations. Dig Dis Sci 2013, 58:509-518.
24. Greydanus M.P., Camilleri M., Colemont L.J., et al. Ileocolonic transfer of solid chyme in small intestinal neuropathies and myopathies. Gastroenterology 1990, 99:158-164.
25. Heaton K.W., Radvan J., Cripps H., et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992, 33:818-824.
26. Andresen V., Camilleri M., Busciglio I., et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007, 133:761-768.
27. Manini M.L., Camilleri M., Goldberg M., et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010, 22:42-49. e7-8.
28. Shimizu Y., Chang E., Shafton A., et al. Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. J Physiol 2006, 576:329-338.
29. Tebbe J., Mronga S., Tebbe C., et al. Ghrelin-induced stimulation of colonic propulsion is dependent on hypothalamic neuropeptide Y1- and corticotrophin-releasing factor 1 receptor activation. J Neuroendocrinol 2005, 17:570-576.